Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2022-08-03 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-08-03 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-03 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-03 English
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by MAIA Biotechnology, Inc. It registers shares of common stock under various equity incentive plans. The text includes detailed legal and procedural information about the registration, indemnification of directors and officers, incorporation by reference of other filings, and exhibits related to stock option plans. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This is a capital markets filing related to equity compensation plans and share registration, not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as registration of shares under stock option plans.
2022-08-01 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 27, 2022, reporting on material definitive agreements including an underwriting agreement related to an initial public offering (IPO), amendments to the company's certificate of incorporation and bylaws, indemnification agreements with directors and officers, and press releases announcing the pricing and closing of the offering. The document includes detailed descriptions of these agreements and corporate governance changes but does not contain financial statements or quarterly/yearly financial results. It is a current report disclosing significant corporate events and transactions rather than a full financial report or earnings release. The primary focus is on financing activities (IPO underwriting agreement, issuance of shares and warrants, use of proceeds) and corporate governance amendments. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-08-01 English
424B4
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus for an initial public offering (IPO) of common stock by MAIA Biotechnology, Inc. It includes information about the offering size, underwriting details, risk factors, business description, management discussion, and financial statements. The presence of underwriting details, offering price, and registration number (333-264225) indicates this is a securities offering prospectus, specifically a 424B4 filing under SEC rules, which is a prospectus supplement related to a public offering. This type of document is primarily a capital raising disclosure and not a financial report, earnings release, or management discussion report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-07-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.